Center for Research in Medical Pharmacology, University of Insubria, Varese, Italy.
Department of Medicine and Surgery, Division of Psychiatry, University of Insubria, Varese, Italy.
Hum Psychopharmacol. 2022 Nov;37(6):e2854. doi: 10.1002/hup.2854. Epub 2022 Sep 7.
Recent studies proposed the existence of a correlation between patients' inflammatory status and therapy response in bipolar disorder (BD). Here we investigated the correlation between levels of inflammatory markers and quetiapine (QUE) effects in BD patients.
In 15 hospitalised BD patients, we investigated changes in inflammatory markers such as C-Reactive Protein (CRP), Erythrocyte Sedimentation Rate (ESR) and cytokines after a 6-week treatment with QUE monotherapy.
We found QUE treatment to significantly reduce CRP and IL-6 plasma levels. Moreover, we found higher CRP and IL-6 plasma levels at baseline correlated with better improvement of patients' clinical symptoms.
The reported results, although preliminary, could be useful in clinical practice, providing not only markers for QUE response, but also allowing for identification of new targets and new therapies for the treatment of this condition.
最近的研究提出，双相情感障碍（BD）患者的炎症状态与治疗反应之间存在相关性。在这里，我们研究了炎症标志物水平与喹硫平（QUE）在 BD 患者中的作用之间的相关性。
在 15 名住院的 BD 患者中，我们研究了 QUE 单药治疗 6 周后炎症标志物（如 C 反应蛋白（CRP）、红细胞沉降率（ESR）和细胞因子）的变化。
我们发现 QUE 治疗可显著降低 CRP 和 IL-6 的血浆水平。此外，我们发现基线时 CRP 和 IL-6 血浆水平较高与患者临床症状的改善更好相关。
尽管这些结果是初步的，但它们在临床实践中可能是有用的，不仅为 QUE 反应提供了标志物，而且为该疾病的治疗确定了新的靶点和新的治疗方法。
